Tarceva Average Treatment Duration Is Approximately Four Months, OSI Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Market opportunity for Tarceva should be evaluated based on mean duration of therapy, which is “a little over four months,” rather than median progression free survival of roughly nine weeks, company says. OSI attempts to correct investor “confusion” about commercial opportunity for the Genentech/OSI lung cancer agent.